CDTX Cidara Therapeutics | $61.73
-0.4% | 6/23/2025 | Steve Brozak | Reiterated Rating | Strong-Buy -> Strong-Buy | $45.00 | View details for WBB Securities rating of Cidara Therapeutics (NASDAQ:CDTX) on 6/23/2025 |
MRKR Marker Therapeutics | $1.23
+1.7% | 4/1/2025 | Steve Brozak | Reiterated Rating | Strong-Buy -> Strong-Buy | $12.50 -> $12.50 | View details for WBB Securities rating of Marker Therapeutics (NASDAQ:MRKR) on 4/1/2025 |
CDTX Cidara Therapeutics | $61.73
-0.4% | 12/5/2024 | - | Boost Price Target | Strong-Buy -> Strong-Buy | $40.00 -> $45.00 | View details for WBB Securities rating of Cidara Therapeutics (NASDAQ:CDTX) on 12/5/2024 |
CDTX Cidara Therapeutics | $61.73
-0.4% | 4/25/2024 | - | Reiterated Rating | Strong-Buy -> Strong-Buy | $40.00 | View details for WBB Securities rating of Cidara Therapeutics (NASDAQ:CDTX) on 4/25/2024 |
CDTX Cidara Therapeutics | $61.73
-0.4% | 9/22/2021 | - | Upgrade | Buy -> Strong-Buy | $125.00 | View details for WBB Securities rating of Cidara Therapeutics (NASDAQ:CDTX) on 9/22/2021 |
OMER Omeros | $3.78
-2.1% | 6/18/2021 | - | Boost Price Target | Strong-Buy | $75.00 -> $100.00 | View details for WBB Securities rating of Omeros (NASDAQ:OMER) on 6/18/2021 |
ARCT Arcturus Therapeutics | $11.98
-1.9% | 6/9/2020 | - | Downgrade | Buy -> Hold | $31.00 | View details for WBB Securities rating of Arcturus Therapeutics (NASDAQ:ARCT) on 6/9/2020 |
CDTX Cidara Therapeutics | $61.73
-0.4% | 12/4/2019 | - | Upgrade | Speculative Buy -> Buy | $125.00 | View details for WBB Securities rating of Cidara Therapeutics (NASDAQ:CDTX) on 12/4/2019 |
ADMA ADMA Biologics | $16.75
-9.7% | 4/4/2019 | - | Upgrade | Buy | | View details for WBB Securities rating of ADMA Biologics (NASDAQ:ADMA) on 4/4/2019 |
MRKR Marker Therapeutics | $1.23
+1.7% | 3/29/2019 | - | Upgrade | Buy -> Strong-Buy | $7.29 | View details for WBB Securities rating of Marker Therapeutics (NASDAQ:MRKR) on 3/29/2019 |
Get the Latest News and Ratings for Your Stocks Enter your email address below to receive the latest headlines and analysts' recommendations for your stocks with our free daily email newsletter. |
ARCT Arcturus Therapeutics | $11.98
-1.9% | 9/20/2018 | - | Upgrade | Buy -> Strong-Buy | | View details for WBB Securities rating of Arcturus Therapeutics (NASDAQ:ARCT) on 9/20/2018 |
SRPT Sarepta Therapeutics | $17.96
+10.5% | 6/20/2018 | - | Reiterated Rating | Buy | | View details for WBB Securities rating of Sarepta Therapeutics (NASDAQ:SRPT) on 6/20/2018 |
ARCT Arcturus Therapeutics | $11.98
-1.9% | 6/11/2018 | - | Upgrade | Hold -> Buy | | View details for WBB Securities rating of Arcturus Therapeutics (NASDAQ:ARCT) on 6/11/2018 |
CDTX Cidara Therapeutics | $61.73
-0.4% | 5/23/2018 | - | Upgrade | Hold -> Buy | | View details for WBB Securities rating of Cidara Therapeutics (NASDAQ:CDTX) on 5/23/2018 |
OMER Omeros | $3.78
-2.1% | 3/26/2018 | - | Reiterated Rating | Buy | $75.00 | View details for WBB Securities rating of Omeros (NASDAQ:OMER) on 3/26/2018 |
CLDX Celldex Therapeutics | $21.21
-1.1% | 12/6/2017 | - | Reiterated Rating | Buy | $150.00 | View details for WBB Securities rating of Celldex Therapeutics (NASDAQ:CLDX) on 12/6/2017 |
ARCT Arcturus Therapeutics | $11.98
-1.9% | 10/9/2017 | - | Upgrade | Hold -> Buy | $2.00 | View details for WBB Securities rating of Arcturus Therapeutics (NASDAQ:ARCT) on 10/9/2017 |
LIVN LivaNova | $48.52
+2.4% | 8/15/2017 | - | Downgrade | Hold -> Sell | $50.00 | View details for WBB Securities rating of LivaNova (NASDAQ:LIVN) on 8/15/2017 |
CDTX Cidara Therapeutics | $61.73
-0.4% | 8/11/2017 | - | Upgrade | Sell -> Hold | | View details for WBB Securities rating of Cidara Therapeutics (NASDAQ:CDTX) on 8/11/2017 |
OMER Omeros | $3.78
-2.1% | 6/14/2017 | - | Reiterated Rating | Strong-Buy | $75.00 | View details for WBB Securities rating of Omeros (NASDAQ:OMER) on 6/14/2017 |
OMER Omeros | $3.78
-2.1% | 3/30/2017 | - | Reiterated Rating | Buy | $75.00 | View details for WBB Securities rating of Omeros (NASDAQ:OMER) on 3/30/2017 |
CDTX Cidara Therapeutics | $61.73
-0.4% | 2/22/2017 | - | Upgrade | Sell -> Hold | $145.00 | View details for WBB Securities rating of Cidara Therapeutics (NASDAQ:CDTX) on 2/22/2017 |
OMER Omeros | $3.78
-2.1% | 11/17/2016 | Stephen Brozak | Reiterated Rating | Buy | $75.00 | View details for WBB Securities rating of Omeros (NASDAQ:OMER) on 11/17/2016 |
ARCT Arcturus Therapeutics | $11.98
-1.9% | 11/2/2016 | - | Upgrade | Sell -> Hold | $4.00 -> $1.90 | View details for WBB Securities rating of Arcturus Therapeutics (NASDAQ:ARCT) on 11/2/2016 |
OMER Omeros | $3.78
-2.1% | 10/17/2016 | Stephen Brozak | Reiterated Rating | Buy | $75.00 | View details for WBB Securities rating of Omeros (NASDAQ:OMER) on 10/17/2016 |
SCYX SCYNEXIS | $0.88
+19.5% | 10/7/2016 | - | Upgrade | Buy -> Strong-Buy | $80.00 | View details for WBB Securities rating of SCYNEXIS (NASDAQ:SCYX) on 10/7/2016 |
CDTX Cidara Therapeutics | $61.73
-0.4% | 9/23/2016 | - | Downgrade | Hold -> Sell | $210.00 | View details for WBB Securities rating of Cidara Therapeutics (NASDAQ:CDTX) on 9/23/2016 |
SRPT Sarepta Therapeutics | $17.96
+10.5% | 9/20/2016 | Stephen Brozak | Reiterated Rating | Strong-Buy | $40.00 -> $60.00 | View details for WBB Securities rating of Sarepta Therapeutics (NASDAQ:SRPT) on 9/20/2016 |
ARCT Arcturus Therapeutics | $11.98
-1.9% | 9/12/2016 | - | Downgrade | Hold -> Sell | $5.00 -> $4.00 | View details for WBB Securities rating of Arcturus Therapeutics (NASDAQ:ARCT) on 9/12/2016 |
LIVN LivaNova | $48.52
+2.4% | 8/31/2016 | - | Reiterated Rating | Hold | $60.00 | View details for WBB Securities rating of LivaNova (NASDAQ:LIVN) on 8/31/2016 |
SCYX SCYNEXIS | $0.88
+19.5% | 8/9/2016 | - | Upgrade | Speculative Buy -> Buy | $80.00 | View details for WBB Securities rating of SCYNEXIS (NASDAQ:SCYX) on 8/9/2016 |
OMER Omeros | $3.78
-2.1% | 6/14/2016 | - | Reiterated Rating | Buy | $75.00 | View details for WBB Securities rating of Omeros (NASDAQ:OMER) on 6/14/2016 |
SRPT Sarepta Therapeutics | $17.96
+10.5% | 6/8/2016 | Stephen Brozak | Reiterated Rating | Buy | $40.00 | View details for WBB Securities rating of Sarepta Therapeutics (NASDAQ:SRPT) on 6/8/2016 |
SRPT Sarepta Therapeutics | $17.96
+10.5% | 5/2/2016 | Stephen Brozak | Reiterated Rating | Strong-Buy | $40.00 | View details for WBB Securities rating of Sarepta Therapeutics (NASDAQ:SRPT) on 5/2/2016 |
SRPT Sarepta Therapeutics | $17.96
+10.5% | 4/26/2016 | Stephen Brozak | Reiterated Rating | Buy | $40.00 | View details for WBB Securities rating of Sarepta Therapeutics (NASDAQ:SRPT) on 4/26/2016 |
SRPT Sarepta Therapeutics | $17.96
+10.5% | 3/30/2016 | Stephen Brozak | Reiterated Rating | Buy | $40.00 | View details for WBB Securities rating of Sarepta Therapeutics (NASDAQ:SRPT) on 3/30/2016 |
TZOO Travelzoo | $9.86
+1.4% | 2/17/2016 | - | Initiated Coverage | Speculative Buy | $11.00 | View details for WBB Securities rating of Travelzoo (NASDAQ:TZOO) on 2/17/2016 |
SCYX SCYNEXIS | $0.88
+19.5% | 1/4/2016 | Stephen Brozak | Initiated Coverage | Buy | $80.00 | View details for WBB Securities rating of SCYNEXIS (NASDAQ:SCYX) on 1/4/2016 |
SCYX SCYNEXIS | $0.88
+19.5% | 12/29/2015 | - | Initiated Coverage | Buy | $80.00 | View details for WBB Securities rating of SCYNEXIS (NASDAQ:SCYX) on 12/29/2015 |
SRPT Sarepta Therapeutics | $17.96
+10.5% | 11/22/2015 | Stephen Brozak | Reiterated Rating | Buy | $40.00 | View details for WBB Securities rating of Sarepta Therapeutics (NASDAQ:SRPT) on 11/22/2015 |
Critical AI announcement set to ignite AI 2.0 (Ad) A new 100% tariff on imported chips just rattled the tech sector—sending some stocks soaring and others tumbling. But for smart traders, this isn’t chaos. It’s opportunity.
One veteran trader is revealing how his simple system spots fast setups in moments like this—no guesswork, no complicated strategies, and no big account required. Click here to see the one pattern built for market volatility—and how to use it. |
CTSO Cytosorbents | $0.89
-1.0% | 10/29/2015 | - | Upgrade | Speculative Buy -> Buy | $13.00 | View details for WBB Securities rating of Cytosorbents (NASDAQ:CTSO) on 10/29/2015 |
CDTX Cidara Therapeutics | $61.73
-0.4% | 10/9/2015 | - | Upgrade | Sell -> Hold | $260.00 | View details for WBB Securities rating of Cidara Therapeutics (NASDAQ:CDTX) on 10/9/2015 |
OMER Omeros | $3.78
-2.1% | 8/18/2015 | - | Boost Price Target | Strong-Buy | $60.00 -> $75.00 | View details for WBB Securities rating of Omeros (NASDAQ:OMER) on 8/18/2015 |
OMER Omeros | $3.78
-2.1% | 8/18/2015 | - | Reiterated Rating | Buy | $60.00 | View details for WBB Securities rating of Omeros (NASDAQ:OMER) on 8/18/2015 |
SRPT Sarepta Therapeutics | $17.96
+10.5% | 8/13/2015 | Stephen Brozak | Reiterated Rating | Buy | $35.00 -> $40.00 | View details for WBB Securities rating of Sarepta Therapeutics (NASDAQ:SRPT) on 8/13/2015 |
ARCT Arcturus Therapeutics | $11.98
-1.9% | 8/9/2015 | - | Reiterated Rating | Hold | $5.00 | View details for WBB Securities rating of Arcturus Therapeutics (NASDAQ:ARCT) on 8/9/2015 |
ARCT Arcturus Therapeutics | $11.98
-1.9% | 6/24/2015 | - | Downgrade | Speculative Buy -> Hold | $5.00 | View details for WBB Securities rating of Arcturus Therapeutics (NASDAQ:ARCT) on 6/24/2015 |
CLDX Celldex Therapeutics | $21.21
-1.1% | 6/1/2015 | Stephen Brozak | Reiterated Rating | Buy | $450.00 -> $600.00 | View details for WBB Securities rating of Celldex Therapeutics (NASDAQ:CLDX) on 6/1/2015 |
SRPT Sarepta Therapeutics | $17.96
+10.5% | 5/22/2015 | Stephen Brozak | Reiterated Rating | Strong-Buy | $25.00 -> $35.00 | View details for WBB Securities rating of Sarepta Therapeutics (NASDAQ:SRPT) on 5/22/2015 |
CDTX Cidara Therapeutics | $61.73
-0.4% | 4/23/2015 | - | Initiated Coverage | Sell | $260.00 | View details for WBB Securities rating of Cidara Therapeutics (NASDAQ:CDTX) on 4/23/2015 |
CTSO Cytosorbents | $0.89
-1.0% | 2/25/2015 | - | Initiated Coverage | Speculative Buy | $13.00 | View details for WBB Securities rating of Cytosorbents (NASDAQ:CTSO) on 2/25/2015 |
SRPT Sarepta Therapeutics | $17.96
+10.5% | 1/15/2015 | Stephen Brozak | Reiterated Rating | Buy | | View details for WBB Securities rating of Sarepta Therapeutics (NASDAQ:SRPT) on 1/15/2015 |
SRPT Sarepta Therapeutics | $17.96
+10.5% | 11/26/2014 | Stephen Brozak | Upgrade | Buy -> Strong-Buy | $25.00 | View details for WBB Securities rating of Sarepta Therapeutics (NASDAQ:SRPT) on 11/26/2014 |
SRPT Sarepta Therapeutics | $17.96
+10.5% | 7/29/2014 | Stephen Brozak | Upgrade | Speculative Buy -> Buy | | View details for WBB Securities rating of Sarepta Therapeutics (NASDAQ:SRPT) on 7/29/2014 |
SRPT Sarepta Therapeutics | $17.96
+10.5% | 7/29/2014 | Stephen Brozak | Boost Price Target | Speculative Buy -> Buy | $25.00 | View details for WBB Securities rating of Sarepta Therapeutics (NASDAQ:SRPT) on 7/29/2014 |
ARCT Arcturus Therapeutics | $11.98
-1.9% | 6/26/2014 | - | Initiated Coverage | Hold | $18.00 | View details for WBB Securities rating of Arcturus Therapeutics (NASDAQ:ARCT) on 6/26/2014 |
OMER Omeros | $3.78
-2.1% | 4/7/2014 | - | Boost Price Target | Strong-Buy | $20.00 -> $30.00 | View details for WBB Securities rating of Omeros (NASDAQ:OMER) on 4/7/2014 |
SRPT Sarepta Therapeutics | $17.96
+10.5% | 11/26/2013 | - | Upgrade | Sell -> Speculative Buy | $9.00 -> $19.00 | View details for WBB Securities rating of Sarepta Therapeutics (NASDAQ:SRPT) on 11/26/2013 |
PATH UiPath | $10.92
-2.7% | 1/22/2013 | - | Upgrade | Buy -> Strong-Buy | $7.00 | View details for WBB Securities rating of UiPath (NYSE:PATH) on 1/22/2013 |
SRPT Sarepta Therapeutics | $17.96
+10.5% | 9/12/2012 | - | Downgrade | Hold -> Sell | $8.00 -> $9.00 | View details for WBB Securities rating of Sarepta Therapeutics (NASDAQ:SRPT) on 9/12/2012 |
BCRX BioCryst Pharmaceuticals | $8.35
-2.9% | 8/14/2012 | - | Downgrade | Buy -> Hold | $8.50 -> $4.40 | View details for WBB Securities rating of BioCryst Pharmaceuticals (NASDAQ:BCRX) on 8/14/2012 |
SRPT Sarepta Therapeutics | $17.96
+10.5% | 8/9/2012 | - | Initiated Coverage | Buy -> Hold | $8.00 | View details for WBB Securities rating of Sarepta Therapeutics (NASDAQ:SRPT) on 8/9/2012 |
VCEL Vericel | $36.15
-0.4% | 7/24/2012 | - | Upgrade | Buy -> Strong-Buy | $3.00 -> $3.00 | View details for WBB Securities rating of Vericel (NASDAQ:VCEL) on 7/24/2012 |
VCEL Vericel | $36.15
-0.4% | 6/4/2012 | - | Upgrade | Speculative Buy -> Buy | $3.00 | View details for WBB Securities rating of Vericel (NASDAQ:VCEL) on 6/4/2012 |
VCEL Vericel | $36.15
-0.4% | 4/16/2012 | - | Upgrade | Hold -> Speculative Buy | $2.50 -> $3.00 | View details for WBB Securities rating of Vericel (NASDAQ:VCEL) on 4/16/2012 |
OMER Omeros | $3.78
-2.1% | 3/22/2012 | - | Boost Price Target | Strong-Buy | $10.50 -> $20.00 | View details for WBB Securities rating of Omeros (NASDAQ:OMER) on 3/22/2012 |
JAZZ Jazz Pharmaceuticals | $112.08
+5.8% | 12/8/2011 | - | Downgrade | Buy -> Hold | $15.00 -> $40.00 | View details for WBB Securities rating of Jazz Pharmaceuticals (NASDAQ:JAZZ) on 12/8/2011 |
VCEL Vericel | $36.15
-0.4% | 12/6/2011 | - | Upgrade | Sell -> Hold | $2.00 -> $2.50 | View details for WBB Securities rating of Vericel (NASDAQ:VCEL) on 12/6/2011 |
GERN Geron | $1.30
-6.5% | 11/16/2011 | - | Downgrade | Strong Buy -> Buy | $19.00 -> $6.00 | View details for WBB Securities rating of Geron (NASDAQ:GERN) on 11/16/2011 |
MBOT Microbot Medical | $2.92
+1.7% | 7/7/2011 | - | Initiated Coverage | Sell | $36.00 | View details for WBB Securities rating of Microbot Medical (NASDAQ:MBOT) on 7/7/2011 |
EBS Emergent Biosolutions | $8.19
+35.8% | 5/31/2011 | - | Boost Price Target | Strong Buy | $20.50 -> $30.00 | View details for WBB Securities rating of Emergent Biosolutions (NYSE:EBS) on 5/31/2011 |
PLX Protalix BioTherapeutics | $1.51
+2.0% | 3/17/2011 | - | Downgrade | Strong-Buy -> Buy | $100.00 | View details for WBB Securities rating of Protalix BioTherapeutics (NYSE:PLX) on 3/17/2011 |
VCEL Vericel | $36.15
-0.4% | 2/9/2011 | - | Initiated Coverage | Sell | $2.00 | View details for WBB Securities rating of Vericel (NASDAQ:VCEL) on 2/9/2011 |
OSIR Osiris Therapeutics | $18.99
| 1/31/2011 | - | Downgrade | Sell -> Sell Short | $5.00 -> $5.00 | View details for WBB Securities rating of Osiris Therapeutics (OTCMKTS:OSIR) on 1/31/2011 |
SRPT Sarepta Therapeutics | $17.96
+10.5% | 12/29/2010 | - | Initiated Coverage | Speculative Buy | $3.00 | View details for WBB Securities rating of Sarepta Therapeutics (NASDAQ:SRPT) on 12/29/2010 |
